other material
confidence high
sentiment positive
materiality 0.70
Cardiff Oncology AACR data: onvansertib shows 73% ORR in bev-naive RAS-mutated mCRC vs 19% in bev-exposed
Cardiff Oncology, Inc.
- Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).
- Onvansertib inhibits hypoxia pathway via HIF1α regulation, reducing tumor vascularization; combo with bevacizumab enhances reduction.
- In RAS WT mCRC PDX models, onvansertib as monotherapy induced stasis/regression in 70% (14/20) of models; combo with cetuximab in 90% (18/20).
- In SCLC cisplatin-resistant PDX models, onvansertib + paclitaxel led to tumor regression lasting 2 months post-treatment.
- CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC to randomize 90 patients to onvansertib 20mg or 30mg plus SoC vs SoC alone.